Elevated serum lactate dehydrogenase isoenzymes and aspartate transaminase distinguish Albers-Schönberg disease (Chloride Channel 7 Deficiency Osteopetrosis) among the sclerosing bone disorders

Journal of Bone and Mineral Research

Volumn 25, Issue 11, 2010, Pages 2515-2526

  Whyte, Michael P ^a,b   Kempa, Lydia G ^a   McAlister, William H ^c   Zhang, Fan ^a   Mumm, Steven ^a,b   Wenkert, Deborah ^a  

^a SHRINERS HOSPITAL FOR CHILDREN   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

^c ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

acid phosphatase; aldolase; bisphosphonate; brain; carbonic anhydrase II deficiency; creatine kinase; enzymopathy; liver disease; muscle; osteoclast; osteosclerosis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BISPHOSPHONIC ACID DERIVATIVE; FRUCTOSE BISPHOSPHATE ALDOLASE; ISOENZYME; LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; ALBERS SCHOENBERG DISEASE; ARTICLE; BONE DISEASE; CHILD; CHLORIDE CHANNEL 7 DEFICIENCY OSTEOPETROSIS; CLINICAL ARTICLE; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; FEMALE; FRACTURE; HUMAN; LOSS OF FUNCTION MUTATION; MALE; PRESCHOOL CHILD; PROTEIN DEFICIENCY; QUANTITATIVE ANALYSIS; SCHOOL CHILD; SCLEROSING BONE DISORDER;

ADOLESCENT; ADULT; ASPARTATE AMINOTRANSFERASES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHLORIDE CHANNELS; CONFIDENCE INTERVALS; CREATINE KINASE; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; FEMALE; HUMANS; ISOENZYMES; L-LACTATE DEHYDROGENASE; MALE; ORGAN SIZE; OSTEOPETROSIS; OSTEOSCLEROSIS; REFERENCE VALUES;

EID: 78349278017     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.130     Document Type: Article

References (59)

1. Whyte MP,. Osteopetrosis. In:, Royce PM, Steinmann B, eds. Connective Tissue and Its Heritable Disorders: Molecular, Genetic, and Medical Aspects, 2nd ed. New York: Wiley-Liss; 2002: 789 -807.
2. Whyte MP,. Sclerosing bone disorders. In:, Rosen CJ, et al., eds. Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th ed. Washington, DC: American Society for Bone and Mineral Research; 2006: 412 -423.
3. Marks SC Jr., Osteopetrosis: multiple pathways for the interception of osteoclast function. Appl Pathol. 1987; 5: 172 -183.
4. Balemans W, Van Wesenbeeck L, Van Hul W,. A clinical and molecular overview of the human osteopetroses. Calcif Tissue Int. 2005; 77: 263 -274.
5. Sobacchi C, Frattini A, Guerrini MM, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet. 2007; 39: 960 -962.
6. Guerrini MM, Sobacchi C, Cassani B, et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet. 2008; 83: 64 -76.
7. Del Fattore A, Peruzzi B, Rucci N, et al. Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: Implications for diagnosis and treatment. J Med Genet. 2006; 43: 315 -325.
8. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S,. Bisphosphonate-induced osteopetrosis. N Eng J Med. 2003; 349: 455 -461.
9. Whyte MP, Chines A, Silva DP, Landt Y, Ladenson JH,. Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders. J Bone Miner Res. 1996; 11: 1438 -1443.
10. Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Vnänen HK, Halleen JM,. Osteoclast derived serum tartrate resistant acid phosphatase 5B in Albers-Schönberg disease (type II autosomal dominant osteopetrosis). Clin Chem. 2004; 50: 883 -890.
11. Waguespack SG, Hui SL, White KE, Buckwalter KA, Econs MJ,. Measurement of tartrate-resistant acid phosphatase and the brain isoenzyme of creatine kinase accurately diagnoses type II autosomal dominant osteopetrosis but does not identify gene carriers. J Clin Endocrinol Metab. 2002; 87: 2212 -2217.
12. Burtis CA, Ashwood ER, (eds). Tietz Textbook of Clinical Chemistry, 2nd ed. Philadelphia, PA: WB Saunders Company; 1994: 812 -819.
13. Ghoshal AK, Soldin SJ,. Evaluation of the Dade Behring Dimension RxL: Integrated chemistry system-pediatric reference ranges. Clin Chim Acta. 2003; 331: 135 -146.
14. Cleiren E, Bénichou O, Van Hul E, et al. Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Molec Genet. 2001; 10: 2861 -2867.
15. Waguespack SG, Koller DL, White KE, et al. Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, Type II. J Bone Miner Res. 2003; 18: 1513 -1518.
16. Whyte MP, Murphy WA, Fallon MD, et al. Osteopetrosis, renal tubular acidosis, and basal ganglia calcification in three sisters. Am J Med. 1980; 69: 64 -74.
17. Sly WS, Whyte MP, Sundaram V, et al. Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. New Engl J Med. 1985; 313: 139 -145.
18. Whyte MP, McAlister WH, Novack DV, Clements KL, Schoenecker PL, Wenkert D,. Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J Bone Miner Res. 2008; 23: 1698 -1707.
19. Eddy MC, Jan De Beur SM, Yandow SM, et al. Deficiency of the alpha-subunit of the stimulatory G protein and severe extraskeletal ossification. J Bone Miner Res. 2000; 15: 2074 -2083.
20. Whyte MP, Wenkert D, McAlister WH, Novack D, Nenninger AR, Mumm S,. Dysosteosclerosis presents as an "osteoclast-poor" form of osteopetrosis: Comprehensive investigation of a 3-year-old girl and literature review. J Bone Miner Res. 2010; 25: 2527 -2539.
21. Eddy MC, Gannon RH, McAlister WH, Green WB, Whyte MP,. Polycystic osteosclerosis with hypercalcemia: a new disorder (abstract). J Bone Miner Res. 1999; 14: S447.
22. Mumm S, Wenkert D, Zhang X, McAlister WH, Mier R, Whyte MP,. Deactivating germline mutations in LEMD3 cause osteopoikilosis and Buschke-Ollendorff syndrome, but not sporadic melorheostosis. J Bone Miner Res. 2007; 22: 243 -250.
23. Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med. 2002; 347: 174 -184.
24. Wenkert D, Mumm S, McAlister WH, Whyte MP,. High bone mass disease with fragile dentition in a Kentucky kindred: a new autosomal dominant disorder (abstract). J Bone Miner Res. 2004; 19: S464.
25. Tebben P, Wenkert D, Novack DV, et al. A new pediatric sclerosing bone disorder featuring fragility fractures (abstract). J Bone Miner Res. 2006; 21: S432.
26. Whyte MP, Essmyer K, Gannon FH, Reinus WR,. Skeletal fluorosis and instant tea. Am J Med. 2005; 118: 78 -82.
27. Whyte MP, Totty WG, Lim VT, Whitford GM,. Skeletal fluorosis from instant tea. J Bone Miner Res. 2008; 23: 759 -769.
28. Villareal DT, Murphy WA, Teitelbaum SL, Arens MQ, Whyte MP,. Painful diffuse osteosclerosis after intravenous drug abuse. Am J Med. 1992; 93: 371 -381.
29. Whyte MP, Reinus WR, Mumm S,. High-bone-mass disease and LRP5 (letter). N Engl J Med. 2004; 350: 2096 -2098.
30. Whyte MP, Totty WG, Novack DV, Wenkert D, Zhang X, Mumm S,. Camurati-Engelmann disease: unique variant featuring a novel mutation in TGFβ1 encoding transforming growth factor beta 1 and a missense change in TNFSF11 encoding RANK ligand. J Bone Miner Res. (in press).
31. Burtis CA, Ashwood ER, Bruns DE, (eds). Tietz Textbook of Clinical Chemistry and Molecular Diagnosis, 4th ed. St. Louis, MO, USA: WB Saunders Company; 2006: 1632 -1633.
32. Vassault A,. Lactate Dehydrogenase, UV-method with pyruvate and NADH, in:, Bergmeyer HU, Gergmeyer JB, Grabl M, Moss DW, eds; Methods in Enzymatic Analysis, 3rd ed., Vol. 3. Weinheim: Verlag Chemie; 1983: 118.
33. Online Mendelian Inheritance in Man, OMIM (TM). McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD), Oct 2, 2009. World Wide Web URL
34. Henry JB,. Clinical Diagnosis and Management by Laboratory Methods, 12th ed., Philadelphia, PA: WB Saunders Company; 2001: 294 -296.
35. Henry RJ, Cannon DC, Winkelman JW, (eds). Clinical Chemistry: Principles and Technics, 2nd ed. New York: Harper & Rowe; 1974: 819 -834.
36. Philp A, Macdonald AL, Watt PW,. Lactate-a signal coordinating cell and systemic function. J Exp Biol. 2005; 208: 4561 -4575.
37. Kopperschläger G, Kirchberger J,. Methods for the separation of lactate dehydrogenases and clinical significance of the enzyme. J Chromatogr B Biomed Appl. 1996; 684: 25 -49.
38. Skillen AW,. Clinical biochemistry of lactate dehydrogenase. Cell Biochem Funct. 1984; 2: 140 -144.
39. Danpure CJ,. Lactate dehydrogenase and cell injury. Cell Biochem Funct. 1984; 2: 144 -148.
40. Commission Enzymologie de la Société Francaise de Biologie. Clinique (SFBC) 1982 Ann Biol Clin 40: 163.
41. Thomas L,. Laktat-Dehydrogenase (LDH) 2-Hydroxybutyrat-Dehydrogenase (HBDH), in Labor and Diagnose-Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik, Die Medizinische Verlagsgesellschaft Margburg, 4. Auflage, 1992; p. 136.
42. Maekawa M,. Lactate dehydrogenase isoenzymes. J Chromatogr. 1988; 429: 373 -398.
43. Bozzuto TM,. Other enzymes. Creatinine phosphokinase, lactate dehydrogenase, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, and alkaline phosphatase. Emerg Med Clin North Am. 1986; 4: 329 -343.
44. Albers-Schönberg HE,. Röntgenbilder einer seltenen Knochenerkrankung. Munch Med Wochenschr. 1904; 51: 365.
45. Czitober H, Moser K, Gründig E,. The marble bone disease of the adult (M. Albers-Schönberg, osteopetrosis). Klin Wsch. 1967; 45: 73 -777.
46. Johnston CC Jr, Lavy N, Lord T, Vellios F, Merritt AD, Deiss WP Jr., Osteopetrosis. A clinical, genetic, metabolic, and morphologic study of the dominantly inherited, benign form. Medicine (Balt). 1968; 47: 149 -167.
47. Bollerslev J, Ueland T, Landaas S, Marks SC Jr., Serum creatine kinase isoenzyme BB in mammalian osteopetrosis. Clin Orthop. 2000; 377: 241 -247.
48. Bollerslev J, Andersen PE Jr., Radiological, biochemical and hereditary evidence of two types of autosomal dominant osteopetrosis. Bone. 1988; 9: 7 -13.
49. Letizia C, Taranta A, Migliaccio S, et al. Type II benign osteopetrosis (Albers-Schönberg disease) caused by a novel mutation in CLCN7 presenting with unusual clinical manifestations. Calcif Tissue Int. 2004; 74: 42 -46.
50. Perrot H, Molinie C, Woehrle R, Thiovolet J,. Cryptogenetic major condensing osteosis associated with a cirrhosis. Lyon Med. 1967; 217: 1237 -1244.
51. Denison EK, Peters RL, Reynolds TB,. Portal hypertension in a patient with osteopetrosis. A case report with discussion of the mechanism of portal hypertension. Arch Intern Med. 1971; 128: 279 -283.
52. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalf FA, Pak CY,. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90: 1294 -1301.
53. Waguespack SG, Hui SL, Dimeglio LA, Econs MJ,. Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation. J Clin Endocrinol Metab. 2007; 92: 771 -778.
54. Kasper D, Planells-Cases R, Fuhrmann JC, et al. Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J. 2005; 24: 1079 -1091.
55. Brandt S, Jentsch TJ,. ClC-6 and ClC-7 are two novel broadly expressed members of the CLC chloride channel family. FEBS. 1995; 377: 15 -20.
56. Kornak U, Kasper D, Bösl MR, et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell. 2001; 104: 205 -215.
57. + antiporter ClC-7 is the primary chloride permeation pathway in lysosomes. Nature. 2008; 453: 788 -792.
58. Lange OF, Wartosch L, Jentsch TJ, Fuhrmann JC,. CIC-7 requires OSTM1 as a beta-subunit to support bone resorption and lysosomal function. Nature. 2006; 440: 220 -223.
59. Frattini A, Pangrazzio A, Susani L,. Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J Bone Miner Res. 2003; 18: 1740 -1747.